Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Common Equity (2016 - 2025)

Collegium Pharmaceutical has reported Common Equity over the past 10 years, most recently at $301.7 million for Q4 2025.

  • Quarterly results put Common Equity at $301.7 million for Q4 2025, up 31.83% from a year ago — trailing twelve months through Dec 2025 was $301.7 million (up 31.83% YoY), and the annual figure for FY2025 was $301.7 million, up 31.83%.
  • Common Equity for Q4 2025 was $301.7 million at Collegium Pharmaceutical, up from $274.8 million in the prior quarter.
  • Over the last five years, Common Equity for COLL hit a ceiling of $301.7 million in Q4 2025 and a floor of $170.0 million in Q1 2021.
  • Median Common Equity over the past 5 years was $209.8 million (2021), compared with a mean of $218.1 million.
  • Biggest five-year swings in Common Equity: soared 62.46% in 2021 and later dropped 21.91% in 2022.
  • Collegium Pharmaceutical's Common Equity stood at $202.9 million in 2021, then decreased by 3.98% to $194.8 million in 2022, then grew by 0.3% to $195.4 million in 2023, then grew by 17.1% to $228.8 million in 2024, then surged by 31.83% to $301.7 million in 2025.
  • The last three reported values for Common Equity were $301.7 million (Q4 2025), $274.8 million (Q3 2025), and $232.2 million (Q2 2025) per Business Quant data.